RUBY Crosses Above Average Analyst Target
January 11, 2021 at 08:12 AM EST
In recent trading, shares of Rubius Therapeutics Inc (RUBY) have crossed above the average analyst 12-month target price of $9.33, changing hands for $9.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..